An association between NQO1 genetic polymorphism and risk of bladder cancer

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 536, Issue 1-2, 2003, Pages 131-137

  Park, Seun Ja ^a   Zhao, Hua ^a   Spitz, Margaret R ^a   Grossman, H Barton ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bladder cancer; Genetic polymorphism; NQO1

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGE; AGED; ALLELE; ARTICLE; BLADDER CARCINOMA; CANCER PATIENT; CANCER RISK; CAUCASIAN; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

EID: 0037457508     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(03)00041-X     Document Type: Article

References (32)

1. Ernster L. DT-diaphorase. Meth. Enzymol. 11:1967;309-317.
2. C. Huggins. Experimental Leukemia and Mammary Cancer, University of Chicago Press, Chicago, 1979.
3. Joseph P., Jaiswal A.K. NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc. Natl. Acad. Sci. U.S.A. 91:1994;8413-8417.
4. Beyer R.E., Segura-Aguilar J., Di Bernardo S., Cavazzoni M., Fato R., Fiorentini D., Galli M.C., Setti M., Landi L., Lenaz G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2528-2532.
5. Siegel D., Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Rad. Biol. Med. 29:2000;246-253.
6. Benson A.M. Conversion of 4-nitroquinoline 1-oxide (4NQO) to 4-hydroxyaminoquinoline 1-oxide by a dicumarol-resistant hepatic 4NQO nitroreductase in rats and mice. Biochem. Pharmacol. 5:1993;1217-1221.
7. Hajos A.K., Winston G.W. Purified NAD(P)H-quinone oxidoreductase enhances the mutagenicity of dinitropyrenes in vitro. J. Biochem. Toxicol. 6:1991;277-282.
8. Traver R.D., Siegel D., Beall H.D., Phillips R.M., Gibson N.W., Franklin W.A., Ross D. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br. J. Cancer. 75:1997;69-75.
9. D. Siegel, A. Anwar, S. Winski, J.K. Kepa, D. Ross, The NQO1*2 polymorphism in NAD(P)H:quinone oxidoreductases 1 targets the protein for proteasomal degradation, Proc. Am. Assoc. Cancer Res. (2000) 227.
10. 609C→T polymorphism with a decreased lung cancer risk Cancer Res. 59:1999;3045-3048.
11. Wiencke J.K., Spitz M.R., McMillan A., Kelsey K.T. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol. Biomarkers Prev. 6:1997;87-92.
12. Xu L.L., Wain J.C., Miller D.P., Thurston S.W., Su L., Lynch T.J., Christiani D.C. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol. Biomarkers Prev. 10:2001;303-309.
13. Rosvold E.A., McGlynn K.A., Lustbader E.D., Buetow K.H. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 5:1995;199-206.
14. Lin P., Wang H.J., Lee H., Lee H.S., Wang S.L., Hsueh Y.M., Tsai K.J., Chen C.Y. NAD(P)H:quinone oxidoreductase polymorphism and lung cancer in Taiwan. J. Toxicol. Environ. Health. 58:1999;187-197.
15. Longuemaux S., Delomenie C., Gallou C., Mejean A., Vincent-Viry M., Bouvier R., Droz D., Krishnamoorthy R., Galteau M.M., Junien C., Beroud C., Dupret J.M. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res. 59:1999;2903-2908.
16. Clairmont A., Sies H., Ramachandran S., Lear J.T., Smith A.G., Bowers B., Jones P.W., Fryer A.A., Strange R.C. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis. 20:1999;1235-1240.
17. 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia Blood. 94:1999;803-807.
18. Lafuente M.J., Casterad X., Trias M., Ascaso C., Molina R., Ballesta A., Zheng S., Wiencke J.K., Lafuente A. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis. 21:2000;1813-1819.
19. Schulz W.A., Krummeck A., Rosinger I., Eickelmann P., Neuhaus C., Ebert T., Schmitz-Drager B.J., Sies H. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 7:1997;235-239.
20. Martone T., Vineis P., Malaveille C., Terracini B. Impact of polymorphisms in xeno(endo)biotic metabolism on pattern and frequency of p53 mutations in breast cancer. Mutat. Res. 462:2000;303-309.
21. Hudmon K.S., Honn S.E., Jiang H., Chamberlain R.M., Xiang W., Ferry G., Gosbee W., Hong W.K., Spitz M.R. Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol. Biomarkers Prev. 6:1997;565-571.
22. Eickelmann P., Schulz W.A., Rohde D., Schmitz-Drager B., Sies H. Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol. Chem. Hoppe. Seyler. 375:1994;439-445.
23. B.S. Weir, Genetic Data Analysis II, Sunderland, Sinauer Associates, Inc., Publishers, Massachusetts, 1996.
24. STATA Corporation STATA Release 7.0 Reference Manual, 6th ed., STATA Corp., College Station, TX, 2000.
25. Nebert D.W., McKinnon R.A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 15:1996;273-280.
26. Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53-depedent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U.S.A. 89:2001;1188-1193.
27. Asher G., Lotem J., Sachs L., Kahana C., Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. U.S.A. 99:2002;13125-13130.
28. Lewis S.J., Cherry N.M., Niven R.M., Barber P.V., Povey A.C. Polymorphisms in the NAD(P)H:quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer. 34:2001;177-183.
29. Yin L., Pu Y., Liu T., Tung T., Chen K., Lin P. Genetic polymorphisms of NAD(P)H:quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer. 33:2001;133-141.
30. Schabath M.B., Spitz M.R., Zhang X., Delclos G.L., Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 21:2000;1163-1166.
31. Zang E.Z., Wynder E.L. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl. Cancer Inst. 88:1996;183-192.
32. Kato R. Sex-related differences in drug metabolism. Drug Metab. Rev. 3:1974;1-32.